RU2017146398A - Экзосомы и их применение в качестве вакцины - Google Patents
Экзосомы и их применение в качестве вакцины Download PDFInfo
- Publication number
- RU2017146398A RU2017146398A RU2017146398A RU2017146398A RU2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A RU 2017146398 A RU2017146398 A RU 2017146398A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- disease
- exosome
- peptide
- animal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 2
- 241001161492 Exosoma Species 0.000 title 1
- 210000001808 exosome Anatomy 0.000 claims 15
- 241001465754 Metazoa Species 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 244000052769 pathogen Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Computing Systems (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (20)
1. Экзосома, выделенная у животного, (а) которое перенесло заболевание, вызванное патогеном, и (b) у которого отсутствует патоген, который вызывает это заболевание.
2. Экзосома по п.1, где животное перенесло вирусное заболевание и у которого отсутствует вирус, который вызывает это заболевание.
3. Экзосома по п.2, где животное является сельскохозяйственным животным.
4. Экзосома по п.3, где сельскохозяйственное животное является свиньей.
5. Экзосома по любому из пп. 1-4, где заболеванием является вирусное респираторное заболевание.
6. Экзосома по любому из пп. 1-5, где животное представляет собой не зараженную вирусом свинью, которая перенесла респираторное вирусное заболевание.
7. Экзосома по п.6, где животное представляет не зараженную вирусом свинью, которая перенесла респираторное заболевание, вызванное вирусом репродуктивно-респираторного синдрома свиней (PRRSV).
8. Экзосома по любому из пп. 1-7, где везикула содержит пептид, содержащий последовательность, выбранную из группы, состоящей из SEQ ID NO:1 и SEQ ID NO:15, и пептид, который по меньшей мере на 85% идентичен любой из последовательностей SEQ ID NO:1-15.
9. Пептид с длиной последовательности, равной или меньшей 100 аминокислот, и содержащий последовательность, выбранную из группы, состоящей из SEQ ID NO:1-15, и последовательность, которая по меньшей мере на 85% идентична последовательности SEQ ID NO:1-15.
10. Пептид по п.9, который представляет собой одну из последовательностей SEQ ID NO:16, 17, 18 или последовательность, которая по меньшей мере на 85% идентична любой из последовательностей SEQ ID NO:16-18:
11. Способ получения внеклеточных везикул по любому из пп. 1-8, который включает выделение экзосом из тестируемого образца животного, (а) которое перенесло заболевание, вызванное патогеном, и (b) у которого отсутствует патоген, который вызывает это заболевание, как определено в любом из предыдущих пунктов.
12. Способ по п.11, где тестируемым образцом является образец сыворотки.
13. Способ по любому из пп. 11-12, где экзосомы отделяют с помощью эксклюзионной хроматографии.
14. Фармацевтическая или ветеринарная композиция, содержащая внеклеточную везикулу, как определено в любом из пп. 1-8, или пептид по любому из пп. 8-9, и один или несколько фармацевтически или ветеринарно приемлемых эксципиентов или носителей.
15. Фармацевтическая или ветеринарная композиция по п.14, которая является вакциной.
16. Экзосома по любому из пп. 1-8 или пептид по любому из пп. 9-10 для применения в качестве иммуногена.
17. Экзосома по любому из пп. 1-8 или пептид по любому из пп. 9-10 для применения в качестве лекарственного средства.
18. Применение экзосомы по любому из пп. 1-8 или пептида по любому из пп. 9-10 при лечении или профилактики вирусного, бактериального или паразитарного заболевания.
19. Способ идентификации пептида, кандидата в иммуногены, включающий стадию анализа белковой композиции экзосомы по любому из пп. 1-8.
20. Применение экзосомы по любому из пп. 1-8 для проведения различия между животными, вакцинированными везикулой по любому из пп. 1-8, и животными, инфицированными тем же патогеном, как патоген, указанный в п.1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201530775 | 2015-06-03 | ||
| ESP201530775 | 2015-06-03 | ||
| PCT/EP2016/062637 WO2016193422A1 (en) | 2015-06-03 | 2016-06-03 | Exosomes and their use as vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017146398A true RU2017146398A (ru) | 2019-07-10 |
| RU2017146398A3 RU2017146398A3 (ru) | 2019-11-05 |
| RU2763524C2 RU2763524C2 (ru) | 2021-12-30 |
Family
ID=56119476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017146398A RU2763524C2 (ru) | 2015-06-03 | 2016-06-03 | Экзосомы и их применение в качестве вакцины |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11020471B2 (ru) |
| EP (1) | EP3302535A1 (ru) |
| CA (1) | CA2992639A1 (ru) |
| MX (1) | MX2017015279A (ru) |
| RU (1) | RU2763524C2 (ru) |
| WO (1) | WO2016193422A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015279A (es) * | 2015-06-03 | 2018-05-15 | Innovex Therapeutics S L | Exasomas y su uso como vacunas. |
| CA3107687A1 (en) * | 2018-02-26 | 2019-08-29 | Claudia Zylberberg | Immune cell activation |
| WO2020037303A1 (en) * | 2018-08-16 | 2020-02-20 | The Regents Of The University Of California | Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof |
| JP2022513311A (ja) * | 2018-09-21 | 2022-02-07 | シティー・ユニバーシティー・オブ・ホンコン | カーゴ積載細胞外小胞 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2785543B1 (fr) * | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
| MX2017015279A (es) * | 2015-06-03 | 2018-05-15 | Innovex Therapeutics S L | Exasomas y su uso como vacunas. |
-
2016
- 2016-06-03 MX MX2017015279A patent/MX2017015279A/es unknown
- 2016-06-03 RU RU2017146398A patent/RU2763524C2/ru active
- 2016-06-03 CA CA2992639A patent/CA2992639A1/en active Pending
- 2016-06-03 EP EP16728659.0A patent/EP3302535A1/en active Pending
- 2016-06-03 WO PCT/EP2016/062637 patent/WO2016193422A1/en active Application Filing
- 2016-06-03 US US15/579,153 patent/US11020471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2992639A1 (en) | 2016-12-08 |
| RU2017146398A3 (ru) | 2019-11-05 |
| EP3302535A1 (en) | 2018-04-11 |
| US11020471B2 (en) | 2021-06-01 |
| US20180161416A1 (en) | 2018-06-14 |
| RU2763524C2 (ru) | 2021-12-30 |
| MX2017015279A (es) | 2018-05-15 |
| WO2016193422A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2899204T3 (es) | Composiciones de vacuna novedosas para el virus de la diarrea epidémica porcina | |
| Yu et al. | Improved immune responses to a bivalent vaccine of Newcastle disease and avian influenza in chickens by ginseng stem-leaf saponins | |
| Chhabra et al. | Immune responses to virulent and vaccine strains of infectious bronchitis viruses in chickens | |
| RU2017146398A (ru) | Экзосомы и их применение в качестве вакцины | |
| Lama et al. | Turbot (Scophthalmus maximus) Nk-lysin induces protection against the pathogenic parasite Philasterides dicentrarchi via membrane disruption | |
| Cibulski et al. | Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice | |
| Hammond et al. | A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| JP2016513956A5 (ru) | ||
| Byadgi et al. | The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum) | |
| FI3534939T3 (fi) | Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi | |
| Sarfraz et al. | Immune responses to in ovo vaccine formulations containing inactivated fowl adenovirus 8b with poly [di (sodium carboxylatoethylphenoxy)] phosphazene (PCEP) and avian beta defensin as adjuvants in chickens | |
| Zhu et al. | Evaluation and characteristics of immunological adjuvant activity of purified fraction of Albizia julibrissin saponins | |
| Snider et al. | The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle | |
| Du et al. | Autophagy and apoptosis induced by Chinese giant salamander (Andrias davidianus) iridovirus (CGSIV) | |
| Sadat et al. | Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle | |
| Li et al. | Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 avian influenza virus in chickens | |
| Trapp et al. | Infectious bursal disease virus’ interferences with host immune cells: what do we know? | |
| RU2021112503A (ru) | Поливалентная вакцина против м. hyo и её применение | |
| Zhang et al. | Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection | |
| Levast et al. | Synthetic cationic peptide IDR-1002 and human cathelicidin LL37 modulate the cell innate response but differentially impact PRRSV replication in vitro | |
| JP2018512152A (ja) | 鳥類ワクチン | |
| Patch et al. | Infection with foot-and-mouth disease virus (FMDV) induces a natural killer (NK) cell response in cattle that is lacking following vaccination | |
| RU2017137498A (ru) | Рекомбинантный нокаутный мутант вируса нодулярного дерматита и его применение | |
| Yuan et al. | Immunoprotection induced by CpG-ODN/Poly (I: C) combined with recombinant gp90 protein in chickens against reticuloendotheliosis virus infection |